[ad_1]
Cambridge, Massachusetts, December 31, 2021 (Global News Agency) – Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a leader in precision genetic medicine for rare diseases, granted an equity award on December 31, 2021. Previously, according to Sarepta’s 2014 employment incentive plan, the remuneration committee of its board of directors approved the equity award as a major employment incentive for 25 people. Incentivized Sarepta to hire the company in December 2021. Approved equity awards in accordance with Nasdaq Listing Rules 5635(c)(4).
In total, employees received options to purchase 19,175 shares of Sarepta common stock and a total of 9,900 restricted stock units (“RSU”). The exercise price of these options is $90.05 per share, which is equivalent to the closing price of Sarepta common stock…
The full story can be found on Benzinga.com
[ad_2]
Source link
